Ruhr-Universität Bochum goto navigation goto content University Homepage
Homepage
Overview
A-Z
Search
Contact

The seal
natural sciences engineering sciences humanities medical institutions central institutions
View of Clinical Research Center

MGO


Home
Members/Staff
Research
Publications
Pancreatic Carcinoma
Links
TeachingFlagge D

Downloads for Students (requires password)

Medical FacultyFlagge D

kkh

MolDiagPaCaFP6

 

PEB

 

 

 

 

Department of

Molecular GI-Oncology
Stephan Hahn, M.D.

Krebshilfe Logo
  Fig Immunohistochemistry Smad Signalling Mutation Analysis Logo MGO
 
 
 
   Deutsch

What's new:


From Bench to Bedside

Asuragen Launches The First Validated microRNA Diagnostic Assay
Austin, Texas – April 23, 2008 – Asuragen, Inc. announced today the launch of the first microRNA (miRNA) test for clinical diagnosis and disease management. The assay utilizes qRT-PCR technology* and differentiates between chronic pancreatitis and pancreatic cancer (pancreatic ductal adenocarcinoma). Pancreatic cancer is the 4th leading cause of cancer related deaths in the United States. Chronic pancreatitis and pancreatic cancer present similar symptoms and can be mis-diagnosed in up to 25% of patients. The test was developed following the discovery of novel microRNAs associated with pancreatic cancer in collaboration between Asuragen scientists and Dr. Stephan Hahn and colleagues at Ruhr University, Bochum, Germany as reported in the journal Oncogene in 2007. According to Dr. Hahn, “The identification of a microRNA, which as far as we know is specific for pancreatic cancer cells, represents a major step forward in supporting new diagnostic strategies for pancreatic diseases.”……

See full version of the press release at http://www.asuragen.com/pdfs/1000-0080%20Press%20Release%20First%20Validated%20Dx%20Assay.pdf

RUBIN Scientific Magazine

New molecular techniques for early detection of pancreatic cancer:

Just a few cells

 
 
Prof. Hahn
There is not much medicine can do when microscopically tiny lesions trigger tumour development in the pancreas. To stop this in the early stages would entail detecting just a few cells from the outside. An interdisciplinary team now wants to make the early stages of cancer visible through molecular imaging, like a “biological magnifying glass”.

 

pdf-versionpdf » rtf-versionrtf » photo dowonloadphotos »

Welcome to the Deptartment of

Molecular GI-Oncology

at Ruhr-University Bochum

School of Medicine

progression model

Contact

Ruhr-University Bochum
Clinical Research Center (ZKF)
Department of Molecular GI-Oncology (MGO)
Universitaetsstrasse 150
44780 Bochum/Germany

Phone Office:  +49 (0) 234 32 29273
Phone Lab:  +49 (0) 234 32 29248
Fax:  +49 (0) 234 32 14674
eMail:  mgo@rub.de

Travel information: How to get here and site plan

 

 
 
back to top  Top | Print
Last update: 20.10.2009 | Imprint | Responsible for: Contents & tech